{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:31:16Z","timestamp":1770510676567,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,12,11]],"date-time":"2014-12-11T00:00:00Z","timestamp":1418256000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s40259-014-0113-2","type":"journal-article","created":{"date-parts":[[2014,12,10]],"date-time":"2014-12-10T10:05:40Z","timestamp":1418205940000},"page":"57-67","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Vedolizumab: A Review of Its Use in Adult Patients with Moderately to Severely Active Ulcerative Colitis or Crohn\u2019s Disease"],"prefix":"10.1007","volume":"29","author":[{"given":"K. P.","family":"Garnock-Jones","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,12,11]]},"reference":[{"issue":"3","key":"113_CR1","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s40265-013-0176-2","volume":"74","author":"M Mosli","year":"2014","unstructured":"Mosli M, Rivera-Nieves J, Feagan B. T-cell trafficking and anti-adhesion strategies in inflammatory bowel disease: current and future prospects. Drugs. 2014;74(3):297\u2013311.","journal-title":"Drugs"},{"issue":"4","key":"113_CR2","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/MOG.0b013e3283622914","volume":"29","author":"PB Allen","year":"2013","unstructured":"Allen PB, Peyrin-Biroulet L. Moving towards disease modification in inflammatory bowel disease therapy. Curr Opin Gastroenterol. 2013;29(4):397\u2013404.","journal-title":"Curr Opin Gastroenterol"},{"key":"113_CR3","unstructured":"Cheng FK, McLean LP, Cross RK. What is the role of vedolizumab in the era of anti-TNF agents? Ann Transl Med. 2014. doi: 10.3978\/j:issn.2305-5839.2013.10.01 ."},{"key":"113_CR4","unstructured":"European Medicines Agency. Entyvio\u00ae (vedolizumab for intravenous infusion): EU summary of product characteristics. 2014. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002782\/WC500168528.pdf . Accessed 28 Oct 2014."},{"key":"113_CR5","unstructured":"Takeda Pharmaceuticals America Inc. Entyvio\u00ae (vedolizumab for intravenous infusion): US prescribing information. 2014. http:\/\/general.takedapharm.com\/content\/file.aspx?filetypecode=ENTYVIOPI&CountryCode=US&LanguageCode=EN . Accessed 28 Oct 2014."},{"issue":"3","key":"113_CR6","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1124\/jpet.109.153973","volume":"330","author":"D Soler","year":"2009","unstructured":"Soler D, Chapman T, Yang LL, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther. 2009;330(3):864\u201375.","journal-title":"J Pharmacol Exp Ther"},{"key":"113_CR7","doi-asserted-by":"crossref","unstructured":"Haanstra KG, Hofman SO, Lopes Estevao DM et al. Antagonizing the alpha4beta1 integrin, but not alpha4beta7, inhibits leukocytic infiltration of the central nervous system in rhesus monkey experimental autoimmune encephalomyelitis. J Immunol. 2013;190(5):1961\u201373.","DOI":"10.4049\/jimmunol.1202490"},{"issue":"1\u20132","key":"113_CR8","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jneuroim.2013.08.011","volume":"264","author":"C Milch","year":"2013","unstructured":"Milch C, Wyant T, Xu J, et al. Vedolizumab, a monoclonal antibody to the gut homing \u03b14\u03b27 integrin, does not affect cerebrospinal fluid T-lymphocyte immunophenotype. J Neuroimmunol. 2013;264(1\u20132):123\u20136.","journal-title":"J Neuroimmunol"},{"issue":"11","key":"113_CR9","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1002\/ibd.22940","volume":"18","author":"ER Fedyk","year":"2012","unstructured":"Fedyk ER, Wyant T, Yang LL, et al. Exclusive antagonism of the alpha4 beta7 integrin by vedolizumab confirms the gut-selectivity of this pathway in primates. Inflamm Bowel Dis. 2012;18(11):2107\u201319.","journal-title":"Inflamm Bowel Dis"},{"issue":"Suppl. 1","key":"113_CR10","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1097\/01.MIB.0000438818.81129.5b","volume":"19","author":"M Rosario","year":"2013","unstructured":"Rosario M, Fox I, Milch C, et al. Pharmacokinetic\/pharmacodynamic relationship and immunogenicity of vedolizumab in adults with inflammatory bowel disease: additional results from GEMINI 1 and 2 [abstract no. P-140]. Inflamm Bowel Dis. 2013;19(Suppl. 1):S80.","journal-title":"Inflamm Bowel Dis"},{"key":"113_CR11","doi-asserted-by":"crossref","unstructured":"Wyant T, Yang L, Fedyk E. In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes. Abs. 2013;5(6):842\u201350.","DOI":"10.4161\/mabs.26392"},{"key":"113_CR12","first-page":"S145","volume":"1","author":"A Parikh","year":"2010","unstructured":"Parikh A, Wyant T, Clifford DB, et al. No increase in JC viremia, lymphocyte count, or circulating CD34+ hematopoietic progenitor cells after treatment with vedolizumab, a humanized monoclonal antibody to alpha4beta7 integrin [abstract no. 1008]. Gastroenterology. 2010;1:S145\u20136.","journal-title":"Gastroenterology"},{"key":"113_CR13","author":"T Wyant","year":"2014","unstructured":"Wyant T, Leach T, Sankoh S, et al. Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. Gut. 2014. doi: 10.1136\/gutjnl-2014-307127 .","journal-title":"Gut"},{"key":"113_CR14","doi-asserted-by":"crossref","unstructured":"Dirks NL, Rosario M, Gastonguay MR et al. Population pharmacokinetic modeling of vedolizumab in patients with ulcerative colitis or Crohn\u2019s disease [abstract no. Mo1225]. Gastroenterology. 2014;146(5 Suppl. 1):S591.","DOI":"10.1016\/S0016-5085(14)62140-5"},{"issue":"8","key":"113_CR15","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1215734","volume":"369","author":"BG Feagan","year":"2013","unstructured":"Feagan BG, Rutgeerts P, Sands BE, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2013;369(8):699\u2013710.","journal-title":"N Engl J Med"},{"issue":"8","key":"113_CR16","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1215739","volume":"369","author":"WJ Sandborn","year":"2013","unstructured":"Sandborn WJ, Feagan BG, Rutgeerts P, et al. Vedolizumab as induction and maintenance therapy for Crohn\u2019s disease. N Engl J Med. 2013;369(8):711\u201321.","journal-title":"N Engl J Med"},{"key":"113_CR17","doi-asserted-by":"crossref","unstructured":"French J, Rosario M, Dirks NL et al. Exposure-response relationship of vedolizumab treatment in adults with ulcerative colitis [abstract no. Mo1229]. Gastroenterology. 2014;146(5 Suppl. 1):S592.","DOI":"10.1016\/S0016-5085(14)62144-2"},{"key":"113_CR18","doi-asserted-by":"crossref","unstructured":"French J, Rosario M, Dirks NL et al. Vedolizumab exposure-response relationship during induction therapy in adults with Crohn\u2019s disease [abstract no. Mo1231]. Gastroenterology. 2014;146(5 Suppl. 1):S592\u2013S3.","DOI":"10.1016\/S0016-5085(14)62146-6"},{"issue":"8","key":"113_CR19","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1002\/ibd.21896","volume":"18","author":"A Parikh","year":"2012","unstructured":"Parikh A, Leach T, Wyant T, et al. Vedolizumab for the treatment of active ulcerative colitis: a randomized controlled phase 2 dose-ranging study. Inflamm Bowel Dis. 2012;18(8):1470\u20139.","journal-title":"Inflamm Bowel Dis"},{"issue":"8","key":"113_CR20","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1097\/MIB.0b013e318281f538","volume":"19","author":"A Parikh","year":"2013","unstructured":"Parikh A, Fox I, Leach T, et al. Long-term clinical experience with vedolizumab in patients with inflammatory bowel disease. Inflamm Bowel Dis. 2013;19(8):1691\u20139.","journal-title":"Inflamm Bowel Dis"},{"key":"113_CR21","doi-asserted-by":"crossref","unstructured":"Feagan BG, McDonald J, Greenberg G et al. An ascending dose trial of a humanized \u03b14\u03b27 antibody in ulcerative colitis (UC) [abstract no. 4851]. Gastroenterology. 2000;118(4 Suppl. 2):A874.","DOI":"10.1016\/S0016-5085(00)85637-1"},{"issue":"24","key":"113_CR22","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa042982","volume":"352","author":"BG Feagan","year":"2005","unstructured":"Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the \u03b14\u03b27 integrin. N Engl J Med. 2005;352(24):2499\u2013507.","journal-title":"N Engl J Med"},{"issue":"12","key":"113_CR23","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1016\/j.cgh.2008.06.007","volume":"6","author":"BG Feagan","year":"2008","unstructured":"Feagan BG, Greenberg GR, Wild G, et al. Treatment of active Crohn\u2019s disease with MLN0002, a humanized antibody to the alpha4beta7 integrin. Clin Gastroenterol Hepatol. 2008;6(12):1370\u20137.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"113_CR24","doi-asserted-by":"crossref","unstructured":"Sands BE, Feagan BG, Rutgeerts P et al. Effects of vedolizumab induction therapy for patients with Crohn\u2019s disease in whom tumor necrosis factor antagonist treatment failed. Gastroenterology. 2014;147(3):618\u201327 e3.","DOI":"10.1053\/j.gastro.2014.05.008"},{"key":"113_CR25","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1016\/S1873-9946(14)60101-X","volume":"8","author":"B Feagan","year":"2014","unstructured":"Feagan B, Colombel JF, Rubin D, et al. Improvements in health-related quality of life in patients with ulcerative colitis treated with vedolizumab [abstract no. DOP076]. J Crohns Colitis. 2014;8:S51\u20132.","journal-title":"J Crohns Colitis"},{"key":"113_CR26","doi-asserted-by":"crossref","first-page":"S276","DOI":"10.1016\/S1873-9946(14)60621-8","volume":"8","author":"B Feagan","year":"2014","unstructured":"Feagan B, Sandborn WJ, Smyth M, et al. Effects of continued vedolizumab therapy for ulcerative colitis in week 6 induction therapy nonresponders [abstract no. P501]. J Crohns Colitis. 2014;8:S276\u20137.","journal-title":"J Crohns Colitis"},{"key":"113_CR27","doi-asserted-by":"crossref","unstructured":"Sandborn WJ, Feagan B, Reinisch W et al. Efficacy of continued vedolizumab therapy in patients with Crohn\u2019s disease who did not respond to vedolizumab induction therapy at week 6 [abstract no. P497]. J Crohns Colitis. 2014;8(Suppl. 1):S274\u2013S5.","DOI":"10.1016\/S1873-9946(14)60617-6"},{"key":"113_CR28","doi-asserted-by":"crossref","first-page":"S502","DOI":"10.14309\/00000434-201310001-01674","volume":"108","author":"JF Colombel","year":"2013","unstructured":"Colombel JF, Sands B, Hanauer S, et al. Long-term safety of vedolizumab for the treatment of ulcerative colitis or crohn\u2019s disease [abstract no. 1674]. Am J Gastroenterol. 2013;108:S502\u20133.","journal-title":"Am J Gastroenterol"}],"updated-by":[{"DOI":"10.1007\/s40259-015-0115-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2015,1,15]],"date-time":"2015-01-15T00:00:00Z","timestamp":1421280000000}}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-014-0113-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40259-014-0113-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-014-0113-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T19:12:21Z","timestamp":1598555541000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40259-014-0113-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,11]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["113"],"URL":"https:\/\/doi.org\/10.1007\/s40259-014-0113-2","relation":{"correction":[{"id-type":"doi","id":"10.1007\/s40259-015-0115-8","asserted-by":"object"}]},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,11]]}}}